NCT03910543View on ClinicalTrials.gov

Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions

Cutaneous SarcoidosisGranuloma Annulare

Interventions

DRUG

Tofacitinib 5 mg twice daily

Tofacitinib will be administered at a dose of 5 mg twice daily

Trial Locations (1)

06519

Yale Center for Clinical Investigation, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Yale University

OTHER

NCT03910543 - Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare | Biotech Hunter | Biotech Hunter